Is psilocybin legal in Australia?

Psilocybin is a Schedule 9 prohibited substance under Australia's Poisons Standard. Possession, use, manufacture and supply outside of specifically authorised channels is a criminal offence. Since February 2023, a narrow Authorised Prescriber pathway has allowed approved clinicians to prescribe psilocybin (as a Schedule 8 controlled drug) for specific patient cohorts. Outside that pathway, the Schedule 9 prohibition applies in full.

Who can legally access psilocybin in Australia in 2024?

Access is restricted to patients under the care of a TGA-approved Authorised Prescriber, operating within the conditions of that approval. There is no legal avenue for individuals to obtain, import or self-administer psilocybin outside this clinical framework. No psilocybin-containing product is listed on the Australian Register of Therapeutic Goods (ARTG) for general supply.

How does psilocybin work pharmacologically?

Psilocybin is a prodrug converted in the body to psilocin, which acts primarily as a partial agonist at 5-HT2A serotonin receptors. Neuroimaging research has observed changes in default mode network activity and altered between-network connectivity. These are mechanistic observations from research settings; they do not describe a predictable individual experience.

When did formal psilocybin research begin?

The first wave of Western clinical research began in the late 1950s and 1960s following Albert Hofmann's isolation and structural identification of psilocybin at Sandoz Laboratories in 1958. Research largely ceased after international drug prohibition in the late 1960s–1970s and did not meaningfully resume until the 1990s and 2000s at institutions including Johns Hopkins University and Imperial College London.

What are the limitations of the current psilocybin research?

Published trials generally have small sample sizes, face challenges with blinding (participants tend to know whether they received an active compound), use heterogeneous outcome measures, and have relatively short follow-up periods. Researchers and regulators have acknowledged these limitations; the evidence base is considered promising but not yet equivalent to a large-scale, long-term controlled evidence base of the kind required for standard therapeutic goods approval.

A History of Psilocybin in Research

By Daniel Okoro · 24 June 2026 · 7 min read

Roughly seventy years of psilocybin research has produced something genuinely strange: a compound that was studied seriously in the 1950s, banned globally for decades, quietly re-examined in the 1990s by a handful of labs, and is now the subject of hundreds of registered clinical trials worldwide. The arc isn't tidy. But the history matters if you want to understand where Australian regulation currently sits , and why.

Before anything else, the legal position in Australia. Psilocybin is listed as a Schedule 9 prohibited substance under the Poisons Standard (the document that gives legal force to Australia's drug scheduling framework). Possession, use, manufacture and supply outside of specific authorised channels is a criminal offence. Since February 2023, the Therapeutic Goods Administration (TGA) has permitted access through a narrow pathway: Authorised Prescribers who have been approved to prescribe psilocybin (rescheduled to Schedule 8 for this purpose) for specific patient cohorts. Outside of that pathway, the substance remains Schedule 9. There is no legal avenue for self-administration, no legal avenue for importation by individuals, and no product containing psilocybin is listed on the Australian Register of Therapeutic Goods. I'll come back to that 2023 decision later. First, the history.

Ceremonial use long before the laboratory

Psilocybin-containing fungi have been used in Mesoamerican ritual contexts for centuries , likely longer. Archaeological evidence from murals and iconographic artefacts in what is now Mexico suggests ritual use predating European contact by a wide margin. The Mazatec people of Oaxaca, in particular, maintained living ceremonial traditions involving Psilocybe species well into the twentieth century. These weren't casual uses; they were highly structured, conducted by trained practitioners called curanderos, and embedded in specific cultural frameworks that bore no resemblance to recreational experimentation.

That context is worth holding onto, because the Western scientific encounter with psilocybin in the late 1950s stripped much of it away.

Albert Hofmann, R. Gordon Wasson, and the 1950s

The Swiss chemist Albert Hofmann , already known for first synthesising lysergic acid diethylamide (LSD) in 1938; isolated and identified psilocybin and psilocin from Psilocybe mexicana specimens in 1958, working at Sandoz Laboratories in Basel. His structural characterisation was published in 1958–59 and remains foundational. Separately, the American ethnomycologist R. Gordon Wasson had published a now-famous account in Life magazine in 1957 describing his participation in a Mazatec ceremony, an account that introduced the concept to mainstream Western readership, albeit through a lens that many later scholars described as romanticised and extractive.

Sandoz subsequently produced synthetic psilocybin and distributed it as a research compound under the name Indocybin to psychiatric researchers in Europe and North America. This is where the first wave of formal clinical investigation began.

The first wave: 1960s psychiatric research

Between roughly 1960 and 1970, a substantial body of research was published examining psilocybin's effects on perception, cognition, and what researchers of the era called "psychotomimetic" states, a framing that positioned the compound as modelling psychosis-like phenomena. The Harvard Psilocybin Project, run by Timothy Leary and Richard Alpert, began in 1960. Some of the work from this period was methodologically poor by contemporary standards: unblinded, lacking control arms, and entangled with the researchers' own philosophical commitments. That's not revisionism; it's documented in the academic record.

There was also more careful work. The 1962 Marsh Chapel Experiment (also at Harvard, led by Walter Pahnke) was an early attempt at a controlled design, examining reported mystical-type experiences under double-blind conditions. Its methodology has since been critiqued, but it's regularly cited as a forerunner of later systematic approaches.

Then the political environment collapsed. By the late 1960s, psilocybin and related compounds were swept into legislative prohibition across the United States (Schedule I under the Controlled Substances Act, 1970) and, progressively, through equivalent scheduling internationally. In Australia, psilocybin was similarly prohibited. Research essentially stopped.

The dormant decades and the quiet revival

The 1970s through the early 1990s produced almost nothing in terms of controlled human research. Ethnobotanical and pharmacological work continued in pockets; the pharmacokinetics of psilocybin were better characterised during this period, and preclinical work on serotonin receptor pharmacology continued, but the human research pipeline had dried up.

The revival began at the University of New Mexico. Researcher Rick Strassman obtained the first US regulatory approval to administer a classical psychedelic in human subjects since the 1970s; his work, published across the 1990s, focused on DMT rather than psilocybin, but it demonstrated that the regulatory pathway could be reopened. Johns Hopkins and the University of California, Los Angeles, followed. Franz Vollenweider's group in Zürich had been working through this period too, often cited for early neuroimaging work pairing psilocybin administration with PET scanning.

By around 2006, the pace was accelerating. A landmark study published in Psychopharmacology by Griffiths and colleagues at Johns Hopkins reported on psilocybin-occasioned experiences in healthy volunteers under rigorously controlled conditions, double-blind, monitor-supported, with careful screening. The reported doses in that study (expressed as mg/70kg in the published text) belong to the scientific record; I won't reproduce them here as a protocol, because the point is the research design, not the numbers.

How psilocybin works: the receptor pharmacology

Psilocybin is a prodrug. After oral ingestion, dephosphorylation in the gut and liver converts it to psilocin, the pharmacologically active form. Psilocin acts primarily as a partial agonist at 5-HT_2A serotonin receptors, which are expressed at high density in cortical regions. This is distinct from the mechanism of cannabinoids acting at the CB1 receptor or the CB2 receptor, though both receptor families are present in overlapping brain regions.

The 5-HT_2A agonism is thought to underlie the perceptual and cognitive alterations psilocybin produces. Neuroimaging studies; including fMRI work from the Imperial College London group led by Robin Carhart-Harris, have identified changes in default mode network activity and increased between-network connectivity. These are observations from research settings. They describe mechanism, not outcome, and they tell us very little about what any individual would experience, which varies substantially depending on setting, expectation, and individual biology.

I'll admit I got this slightly wrong for years: I used to conflate the 5-HT_2A effects with serotonin-syndrome risk in the way older sources described it. The pharmacology is more nuanced than that, and researchers now draw careful distinctions between agonist profiles at different serotonin receptor subtypes.

The second wave and current trial landscape

By the 2010s, research groups at Imperial College London, Johns Hopkins, NYU, and MAPS (the Multidisciplinary Association for Psychedelic Studies) had published multiple trials examining psilocybin-assisted protocols. These are published, peer-reviewed trials with registered methodologies, not anecdote. But they also, uniformly, have limitations: small sample sizes, difficulty achieving true blinding (participants generally know whether they've received an active compound), heterogeneous outcome measures, and relatively short follow-up periods. Anyone citing these results as definitive should read the limitations sections.

In my view, the popular coverage has run well ahead of what the evidence base actually supports. That's not a reason to dismiss the research; it's a reason to read the primary papers rather than the press releases.

Australia's 2023 TGA decision to reschedule psilocybin (alongside MDMA) for use by Authorised Prescribers placed Australia among the first jurisdictions globally to permit a formal clinical access pathway outside of trials. The decision followed the TGA's review of a body of trial data and a specific access pathway already existing through the Special Access Scheme. To be precise: the Schedule 8 rescheduling applies only within the Authorised Prescriber framework. Psilocybin obtained outside that framework, whether synthesised, cultivated, or imported, remains Schedule 9 prohibited, and criminal penalties apply. The ADF (Australian Drug Foundation) has published clear public guidance on this distinction.

What the research record does and doesn't tell us

Seventy years of investigation have produced a reasonably detailed picture of psilocybin's receptor pharmacology, its metabolic conversion from prodrug to active form, and its acute perceptual and cognitive effects in research settings. What it hasn't produced is a large-scale, long-term, placebo-controlled evidence base comparable to that required for standard TGA approval of a therapeutic good. The trials are promising enough to have justified the regulatory pathway that now exists. They are not yet settled science.

The history also carries a warning embedded in the 1960s collapse: when research becomes entangled with countercultural politics, it tends to generate a prohibitionist backlash that sets the science back by decades. The current revival has, mostly, maintained institutional discipline. Whether that holds as the research gets more visible and more commercially interesting is genuinely unclear.

I was reading through some of the old Sandoz correspondence archives last year; between jazz practice sessions, yes, and what struck me was how careful Hofmann was to separate the chemistry from the interpretation. The molecule was the molecule. Everything else was context. That distinction still does a lot of work.

Sources

, Daniel Okoro, Psychedelic science & law writer

Common questions

Is psilocybin legal in Australia?: Psilocybin is a Schedule 9 prohibited substance under Australia's Poisons Standard. Possession, use, manufacture and supply outside of specifically authorised channels is a criminal offence. Since February 2023, a narrow Authorised Prescriber pathway has allowed approved clinicians to prescribe psilocybin (as a Schedule 8 controlled drug) for specific patient cohorts. Outside that pathway, the Schedule 9 prohibition applies in full.
Who can legally access psilocybin in Australia in 2024?: Access is restricted to patients under the care of a TGA-approved Authorised Prescriber, operating within the conditions of that approval. There is no legal avenue for individuals to obtain, import or self-administer psilocybin outside this clinical framework. No psilocybin-containing product is listed on the Australian Register of Therapeutic Goods (ARTG) for general supply.
How does psilocybin work pharmacologically?: Psilocybin is a prodrug converted in the body to psilocin, which acts primarily as a partial agonist at 5-HT2A serotonin receptors. Neuroimaging research has observed changes in default mode network activity and altered between-network connectivity. These are mechanistic observations from research settings; they do not describe a predictable individual experience.
When did formal psilocybin research begin?: The first wave of Western clinical research began in the late 1950s and 1960s following Albert Hofmann's isolation and structural identification of psilocybin at Sandoz Laboratories in 1958. Research largely ceased after international drug prohibition in the late 1960s–1970s and did not meaningfully resume until the 1990s and 2000s at institutions including Johns Hopkins University and Imperial College London.
What are the limitations of the current psilocybin research?: Published trials generally have small sample sizes, face challenges with blinding (participants tend to know whether they received an active compound), use heterogeneous outcome measures, and have relatively short follow-up periods. Researchers and regulators have acknowledged these limitations; the evidence base is considered promising but not yet equivalent to a large-scale, long-term controlled evidence base of the kind required for standard therapeutic goods approval.